SCHEMBL1849376

SCHEMBL1849376

CC(Sc1ccccc1Br)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
PRNP P04156 2/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAP2K7 O14733 1/20 0.45
ELANE P08246 1/20 0.45
CDC25A P30304 1/20 0.45
CDC25B P30305 1/20 0.45
MAPK10 P53779 1/20 0.45
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
PTGS2 P35354 1/20 0.42
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 2/20 0.40
PPARA Q07869 2/20 0.39
HTT P42858 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13603779 0.86 RXFP1 (0.54) RXFP1NPSR1SMN1; SMN2PRNPKDM4E
SCHEMBL11599814 0.79 LMNA (0.38) ALDH1A1MAOAMAOBLMNAPPARA
SCHEMBL9849600 0.79 RXFP1 (0.49) RXFP1NPSR1SMN1; SMN2PRNPKDM4E
SCHEMBL11517389 0.79 RXFP1 (0.50) RXFP1NPSR1SMN1; SMN2PRNPKDM4E
SCHEMBL9849304 0.78 RXFP1 (0.49) RXFP1NPSR1SMN1; SMN2PRNPKDM4E
SCHEMBL11522249 0.78 RXFP1 (0.47) RXFP1NPSR1SMN1; SMN2PRNPKDM4E
SCHEMBL10745516 0.78 POLB (0.63) RXFP1NPSR1SMN1; SMN2PRNPKDM4E
SCHEMBL10589041 0.78 NPSR1 (0.49) RXFP1NPSR1SMN1; SMN2PRNPKDM4E
SCHEMBL1850599 0.77 PKM (0.44) RXFP1NPSR1SMN1; SMN2PRNPKDM4E
SCHEMBL2911430 0.76 MAOA (0.52) ALDH1A1MAP2K7ELANECDC25ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 RXFP1 98/4885NPSR1 106/4885SMN1; SMN2 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.